Highlights • The phase 3 study includes only patients with intermediate risk prostate cancer. • The addition of short-course hormonal therapy leads to improved outcomes. • Short-term ADT combined with lower dose of radiotherapy is feasible and yields to a better toxicity profile.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Éric
Contact Éric, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack